Novo Nordisk Wins EMA Approval for Flexible Wegovy Storage
Novo Nordisk gains EMA approval for Wegovy injection storage at up to 30°C for 48 hours, improving delivery flexibility for obesity treatment across Europ
- EMA approved storage of Wegovy injection at up to 30°C for 48 hours during final-stage delivery, easing cold-chain requirements.
- Change applies only to the SmPC for healthcare providers — patient instructions and leaflets remain unchanged.
- Wegovy is now the only GLP-1 weight-management therapy in Europe with this delivery flexibility.
- After first use, patients still store the pen below 30°C for up to 28 days — that rule hasn't changed.
- Update excludes the Wegovy pill; its EU decision is expected later in 2026.
What the EMA Approval Changes
The European Medicines Agency has approved an update to the product information for Wegovy injection, allowing it to be stored at up to 30°C for up to 48 hours during delivery. This change significantly eases distribution requirements, making Wegovy the only GLP-1 therapy for weight management in Europe with this level of flexibility.
Previously, Wegovy distribution relied entirely on strict cold chain logistics, requiring continuous refrigeration from manufacturing to patient use. With this new approval, the final stage of delivery — from pharmacies to patients — can now occur within a 48-hour window without refrigeration, provided temperatures do not exceed 30°C.
Why Cold-Chain Flexibility Matters
"Home delivery of medicines is growing rapidly, given the convenience of being able to receive your medicines at your doorstep, which we have come to expect from most other aspects of our lives. People with obesity using prescription medicine may also face stigma, and we are therefore excited about the opportunity to reduce distribution complexity while further enabling discrete home delivery options," said Mike Doustdar, CEO and president of Novo Nordisk.
This added flexibility is expected to support the growth of eHealth and direct-to-patient delivery models, including online pharmacies and alternative dispensing channels. It may also reduce logistical costs by lowering packaging requirements and minimizing reliance on temperature-controlled transport systems.
This flexibility comes as Novo Nordisk faces mounting supply pressure — Wegovy demand is already straining peptide manufacturing capacity, making distribution efficiency even more critical as the company scales output.
What This Means for Patients and Pharmacies
The update applies specifically to healthcare providers through changes in the Summary of Product Characteristics (SmPC), with no revisions to patient leaflets. Patients can continue storing the injection for up to 28 days below 30°C after first use. The update does not apply to the Wegovy pill, which does not require refrigeration and is currently approved in the U.S., with a European regulatory decision anticipated later in 2026.
Source: Wegovy's revised 30°C/48-hour storage conditions are published in the official EU Summary of Product Characteristics.
Reporting on the science, business and regulation shaping the pharmaceutical industry.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion